ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly cOVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%)
Annual figures from Eli Lilly's filings and investor materials
Latest, FY2023
-100.0%
Period ended Dec 31, 2023
Change on a year earlier
-90.0 pts
-10.0% in FY2022
History
2 years
Since FY2022
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | -100.0% | -90.0 pts | Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | -10.0% | – | Form 10-K FY2022 (filed 2023-02-22) ↗ |
Cite this data
StockData. (2026). Eli Lilly COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy] (%), annual FY2022–FY2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_covid19antibodies_yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.